Related Experiment Videos
Atrial fibrillation following physostigmine
Canadian Anaesthetists' Society Journal
|July 1, 1983
Summary
Physostigmine, an anticholinesterase, can cause atrial fibrillation as a rare side effect. This case report details a self-limiting cardiac event following a standard dose, highlighting the need for careful patient monitoring.
Area of Science:
- Anesthesiology
- Pharmacology
- Cardiology
Background:
- Physostigmine is an anticholinesterase agent used to reverse anesthetic-induced central nervous system and respiratory depression.
- It is generally considered to have mild side effects.
- Its use is indicated for specific conditions following general anesthesia.
Observation:
- A patient experiencing delayed recovery from general anesthesia received a total dose of 2 mg of physostigmine.
- Following administration, the patient developed atrial fibrillation.
Findings:
- The atrial fibrillation was a self-limiting event.
- No specific therapeutic intervention was required for the arrhythmia.
- This suggests a potential, albeit rare, cardiac side effect of physostigmine.
Implications:
- Physicians should be aware of the potential for cardiac arrhythmias, such as atrial fibrillation, with physostigmine use.
- Careful patient selection and monitoring are crucial when administering physostigmine, especially in patients with pre-existing cardiac conditions or delayed anesthetic recovery.
- Further investigation into the specific mechanisms and incidence of physostigmine-induced arrhythmias may be warranted.